This session will explore the importance and evolution of clinical site accreditation. Learn about best practices, standards, regulatory differences, and how these factors align to bring quality and consistency to clinical trial sites.
This session will provide an overview of the required documentation for clinical research participants in HealthLink, UW Health’s electronic health record.
Learn more about theranostics and how theranostics-related research is conducted.
Learn more about the current state of clinical research at UW–Madison, as well as what's on the horizon for the clinical research community in 2023.
Explore best practices and considerations for fiscal planning and management of clinical trials at UW–Madison, including budgeting tools, fees to include, and negotiation tips.
As a follow-up to our 'UW Clinical Research Update' session in January, this will be an open question and answer forum.
Learn tips for what to do before, during, and after an FDA audit of a clinical trial.
Learn what bias is, see examples of how it shows up in healthcare, the language we use, and clinical trials. Also, learn a few strategies to move towards a more race-conscious approach that will address our unconscious biases.
Engage with leaders within the UW clinical research community at this open Q+A ‘Research Forum’. This is an opportunity to ask questions about clinical research-related topics such as the IRB, informatics, and clinical trials.
Learn more about the Industry-sponsored Clinical Trials Budget Template, its supporting documentation, and how to access/use it in OnCore. Also, hear about lessons learned from the 8-month pilot and suggestions and best practices for using the template. The Budget Template will launch July 1 and will be required for industry sponsored clinical trials at UW moving forward.
Learn from the IRB what types of events constitute potential unanticipated problems or noncompliance that require report to the IRB as a "reportable event".
Learn about clinical research that is focused on the safety and novel therapeutic use of psychoactive medications, including psilocybin for depression and substance use disorder and MDMA for PTSD.
